The treatment of spasticity poses a major challenge in the management of patients with (ALS). Sativex approved for the treatment of spasticity in multiple sclerosis. It is an extra treatment option . But not listed on the ALS spasticity label.
In fact, a monocentric retrospective cohort study was conducted in 32 patients with amyotrophic lateral sclerosis with spasticity. These patients had access to treatment with Sativex cannabis spray. with an average dose of 5.5 sprays (between 1 and 20 doses per day).
CBD & spasticity
It took place at the center for ALS and other motor disorders. In Charité, at the University of Medicine, in Berlin, Germany.
The average satisfaction levels found (greatest value 100) were: efficiency 70.5, convenience 76.6 and overall satisfaction 75.0.
In short, the results suggest that the combination of THC: CBD could be a valuable addition to the symptomatic ALS treatment.